89BIO (ETNB)
(Real Time Quote from BATS)
$8.49 USD
+0.23 (2.79%)
Updated Apr 29, 2024 03:48 PM ET
After-Market: $8.53 +0.04 (0.47%) 4:08 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
ETNB 8.49 +0.23(2.79%)
Will ETNB be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ETNB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ETNB
Novo Nordisk (NVO) Down Despite Kidney Outcomes Study Success
Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study
ETNB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Believe 89BIO (ETNB) Could Rally 121.5%: Here's is How to Trade
89BIO (ETNB) Just Overtook the 200-Day Moving Average
89BIO (ETNB) Recently Broke Out Above the 20-Day Moving Average
Other News for ETNB
Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage
3 Potential Biopharma Buyout Targets
89bio assumed with a Buy at BofA
Hepion ends Phase 2 study for NASH drug due to cash restraints
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors